Get more exposure for your business with the new HTML5 flipbooks. Learn more

A Review of Tofacitinib Drugs & Pros. and Cons. of Pharmaceutica

Jenifer Weisz


Published on January 25, 2016

One of the most generally reported adverse responses throughout the very first 3 months in regulated medical tests (happening in greater than or equal to 2 % of clients treated with tofacitinib citrate monotherapy or in combo with DMARDs) were upper respiratory tract infections, frustration, diarrhea, and nasopharyngitis (the "common cold"). Manusaktteva is the leading manufacturer of tofacitinib citrate in india.

Similar publications